1. Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma
   W. B. Pope et al, 2011, American Journal of Neuroradiology CrossRef
2. The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas
   Chul-Kee Park et al, 2012, Translational Oncology CrossRef
3. O6-methylguanine-DNA methyltransferase (MGMT): impact on cancer risk in response to tobacco smoke
   Markus Christmann et al, 2012, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis CrossRef
4. A Consideration ofMGMTGene Promotor Methylation Analysis for Glioblastoma Using Methylation-Specific Polymerase Chain Reaction and Pyrosequencing
   Sang Hwa Lee et al, 2011, Korean J Pathol CrossRef
5. Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma
   Ying-Li Lin et al, 2012, Int Urol Nephrol CrossRef
6. Relationship between GSTM1/GSTT1 Null Genotypes and Renal Cell Carcinoma Risk: A Meta-Analysis
   Hui-Yuan Cheng et al, 2012, Renal Failure CrossRef
7. A meta-analysis of the relationship between glutathione S-transferase T1 null/presence gene polymorphism and the risk of lung cancer including 31802 subjects
   Hua-Fu Zhou et al, 2013, Mol Biol Rep CrossRef
8. A meta-analysis of the relationship between glutathione S-transferases gene polymorphism and hepatocellular carcinoma in Asian population
   Jie Chen et al, 2012, Mol Biol Rep CrossRef
9. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction
   Marta Brell et al, 2011, BMC Cancer CrossRef
10. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models
    Ling Cen et al, 2013 CrossRef
11. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme
    Leonard Sunwoo et al, 2013, J. Magn. Reson. Imaging CrossRef
12. LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer
    W-b Liu et al, 2013, Cell Death Dis CrossRef
13. Molecular alterations in glioblastoma: potential targets for immunotherapy.
    Azizul Haque et al, 2011 CrossRef
14. Effect of TET1 regulating MGMT on chemotherapy resistance of oral squamous cell carcinoma stem cells.
    Wei Wang et al, 2018, J Cell Biochem CrossRef
15. Lhx6 and Lhx8: cell fate regulators and beyond
    Chen Zhou et al, 2015, The FASEB Journal CrossRef
16. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.
    Shabierjiang Jiapaer et al, 2018, Neurol Med Chir (Tokyo) CrossRef
17. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies.
    Joana Balça-Silva et al, 2019, Semin Cancer Biol CrossRef
18. Glioblastoma Recurrence and the Role of O6-Methylguanine–DNA Methyltransferase Promoter Methylation
    Katie Storey et al, 2019, JCO Clinical Cancer Informatics CrossRef
19. Chemoresistance in Glioma
    Stella Sun et al, 2013 CrossRef
20. Cell-specific pattern of berberine pleiotropic effects on different human cell lines
    Alessandro Agnarelli et al, 2018, Sci Rep CrossRef
21. Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review
    Jonas Feldheim et al, 2019, Cancers CrossRef
22. Treatment Results for Recurrent Glioblastoma and Alteration of Programmed Death-Ligand 1 Expression After Recurrence
    Kyoung Su Sung et al, 2019, World Neurosurgery CrossRef
23. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence
    Radhika Mathur et al, 2020 CrossRef
24. PARP inhibition suppresses the emergence of temozolomide resistance in a model system
    Alice L. Yuan et al, 2020, J Neurooncol CrossRef
25. MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features
    H.J. Choi et al, 2021, AJNR Am J Neuroradiol CrossRef
26. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
    Alexandra McAleenan et al, 2021 CrossRef
27. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: a single-center retrospective series
    Nicola Montemurro et al, 2021, Clinical Neurology and Neurosurgery CrossRef
28. Quantitative analysis of MGMT promoter methylation status changes by pyrosequencing in recurrent glioblastoma.
    Víctor González Jiménez et al, 2022, Neuropathology CrossRef
29. Unraveling the mysteries of MGMT: Implications for neuroendocrine tumors
    null JianyunJiang et al, 2024, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
30. Advanced Distance-Resolved Evaluation of the Perienhancing Tumor Areas with FLAIR Hyperintensity Indicates Different ADC Profiles byMGMTPromoter Methylation Status in Glioblastoma
    Gergely Bertalan et al, 2025, AJNR Am J Neuroradiol CrossRef